Next Article in Journal
The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid Arthritis
Next Article in Special Issue
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Previous Article in Journal
T Helper 17 Cells in Primary Sjögren’s Syndrome
Previous Article in Special Issue
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
J. Clin. Med. 2017, 6(7), 66; doi:10.3390/jcm6070066

When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia

1
Pediatric Hematology/Oncology, Oregon Health & Science University, Portland, OR 97239, USA
2
Pediatric Hematology/Oncology/Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI 53226, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Marco Ladetto and Jane Grant-Kels
Received: 25 April 2017 / Revised: 26 June 2017 / Accepted: 3 July 2017 / Published: 7 July 2017
(This article belongs to the Special Issue Role of Minimal Residual Disease Assessment in Hematological Cancers)
View Full-Text   |   Download PDF [228 KB, uploaded 7 July 2017]

Abstract

The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) has become the most important prognostic tool of, and the backbone to, upfront risk stratification. While MRD assessment is the standard of care for assessing response and predicting outcomes for pediatric patients with ALL receiving chemotherapy, its use in allogeneic hematopoietic stem cell transplant (HSCT) has been less clearly defined. Herein, we discuss the importance of MRD assessment during the peri-HSCT period and its role in prognostication and management. View Full-Text
Keywords: ALL; pediatric; transplant; leukemia; minimal residual disease ALL; pediatric; transplant; leukemia; minimal residual disease
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lamble, A.; Phelan, R.; Burke, M. When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia. J. Clin. Med. 2017, 6, 66.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top